 |
[Apha Biz=(Chicago) Reporter Paul Lee] Aprogen, a company specializing in antibody drug development, announced on the 5th that it has developed a new sialophorin antibody that binds to blood cancer cell surface antigen in combination with CD3 antibody and completed patent application.
Antibodies developed by Aprogen combine with acute leukemia cancer cell surface proteins with up to 1,460% higher binding force than conventional antibodies. Cyalusporin is known to exist in excess at a high frequency not only in leukemia cancer cells but also in colorectal cancer cells.
Aprogen has been developing treatments for acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL) using antibodies that do not bind to the sialophorin of normal cells but only to cancer cells such as acute leukemia and its patented CHIMPS double antibody technology. Dual antibodies employ CD3 antibodies that bind to killer T cells like existing antibodies, which attract killer T immune cells and attach them to cancer cells.
As a result, five types of antibodies applied for the patent, showing an increase in the binding force of target antigens by at least 490 percent and up to 1,460 percent compared to existing antibodies.
AlphaBIZ 폴 리(hoondork1977@alphabiz.co.kr)
